In addition to CCR4, its ligands CCL17 and CCL22 found to be elevated in liver cancer, which facilitate Tregs cell infiltration to the tumors leading to the suppression of anti-cancer immunity by TGF-β1 production, and further establishment of a favorable microenvironment for tumor growth [36, 37]. This evidence concerns the gene CCL22 and neoplasm.